H Zhou1, Y Shen2, Z Zhang1, X Liu2, J Zhang3, J Chen4. 1. The Third Clinical Medical School of Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. 2. Department of Hernia and Abdominal Wall Surgery, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. 3. Department of General Surgery, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, China. txzhangjian@126.com. 4. Department of Hernia and Abdominal Wall Surgery, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, 100020, China. chenjiejoe@sina.vip.com.
Abstract
PURPOSE: We conducted a network meta-analysis to evaluate potential differences in patient outcomes when different meshes, especially biological meshes, were used for ventral hernia repair. METHODS: PubMed, Embase, Cochrane Library, and Clinical Trials.gov databases were searched for studies comparing biological meshes with biological or synthetic meshes for ventral hernia repair. The outcomes were hernia recurrence rate, surgical site infection, and seroma. We performed a two-step network meta-analysis to investigate the outcomes of several biological meshes: non-cross-linked human acellular dermal matrix (NCHADM), non-cross-linked porcine ADM (NCPADM), non-cross-linked bovine ADM (NCBADM), cross-linked porcine ADM (CPADM), and porcine small intestinal submucosa (PSIS). RESULTS: From 6304 publications, 23 studies involving 2603 patients were finally included. We found no differences between meshes in recurrence at 1-year follow-up and in surgical site infection rate. NCBADM was associated with the lowest recurrence rate and the lowest surgical site infection rate. NCHADM implantation was associated with the lowest rate of seroma. PSIS was associated with a higher risk of seroma than NCHADM (pooled risk ratio 3.89, 95% confidence interval 1.13-13.39) and NCPADM (RR 3.42, 95% CI 1.29-9.06). CONCLUSIONS: Our network meta-analysis found no differences in recurrence rate or surgical site infection among different biological meshes. The incidence of postoperative seroma was higher with PSIS than with acellular dermal matrices. We observed large heterogeneity in the studies of ventral hernia repair using biological meshes, and, therefore, well-designed randomized clinical trials are needed.
PURPOSE: We conducted a network meta-analysis to evaluate potential differences in patient outcomes when different meshes, especially biological meshes, were used for ventral hernia repair. METHODS: PubMed, Embase, Cochrane Library, and Clinical Trials.gov databases were searched for studies comparing biological meshes with biological or synthetic meshes for ventral hernia repair. The outcomes were hernia recurrence rate, surgical site infection, and seroma. We performed a two-step network meta-analysis to investigate the outcomes of several biological meshes: non-cross-linked human acellular dermal matrix (NCHADM), non-cross-linked porcine ADM (NCPADM), non-cross-linked bovine ADM (NCBADM), cross-linked porcine ADM (CPADM), and porcine small intestinal submucosa (PSIS). RESULTS: From 6304 publications, 23 studies involving 2603 patients were finally included. We found no differences between meshes in recurrence at 1-year follow-up and in surgical site infection rate. NCBADM was associated with the lowest recurrence rate and the lowest surgical site infection rate. NCHADM implantation was associated with the lowest rate of seroma. PSIS was associated with a higher risk of seroma than NCHADM (pooled risk ratio 3.89, 95% confidence interval 1.13-13.39) and NCPADM (RR 3.42, 95% CI 1.29-9.06). CONCLUSIONS: Our network meta-analysis found no differences in recurrence rate or surgical site infection among different biological meshes. The incidence of postoperative seroma was higher with PSIS than with acellular dermal matrices. We observed large heterogeneity in the studies of ventral hernia repair using biological meshes, and, therefore, well-designed randomized clinical trials are needed.
Authors: R W Luijendijk; W C Hop; M P van den Tol; D C de Lange; M M Braaksma; J N IJzermans; R U Boelhouwer; B C de Vries; M K Salu; J C Wereldsma; C M Bruijninckx; J Jeekel Journal: N Engl J Med Date: 2000-08-10 Impact factor: 91.245
Authors: M P Morris; J A Mellia; A N Christopher; M N Basta; V Patel; K Qiu; R B Broach; J P Fischer Journal: Hernia Date: 2021-01-19 Impact factor: 4.739
Authors: Jeremy Warren; Shivani S Desai; Nicole D Boswell; Benjamin H Hancock; Hamza Abbad; Joseph A Ewing; Alfredo M Carbonell; William S Cobb Journal: J Am Coll Surg Date: 2020-01-16 Impact factor: 6.113
Authors: Marc Miserez; Rolf Lefering; Federico Famiglietti; Tim Mathes; Dörthe Seidel; Stefan Sauerland; Dragan Korolija; Markus Heiss; Gyorgy Weber; Ferdinando Agresta; Willem-Hans Steup; Maciej Śmietański; Rui Ribeiro; Diego Cuccurullo; Fausto Catena; Claudia Rudroff; Georg Rosanelli; Fabian Schön; Bart Smet; Frank Wenger; Stefano Saad; Lars Naver; Edmund Neugebauer Journal: Ann Surg Date: 2021-01-01 Impact factor: 12.969
Authors: Michael J Rosen; Joel J Bauer; Marco Harmaty; Alfredo M Carbonell; William S Cobb; Brent Matthews; Matthew I Goldblatt; Don J Selzer; Benjamin K Poulose; Bibi M E Hansson; Camiel Rosman; James J Chao; Garth R Jacobsen Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: S G Parker; S Mallett; L Quinn; C P J Wood; R W Boulton; S Jamshaid; M Erotocritou; S Gowda; W Collier; A A O Plumb; A C J Windsor; L Archer; S Halligan Journal: BJS Open Date: 2021-03-05